Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Drug Type
- Biotech
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
Allo HSCT for High Risk Hemoglobinopathies
- Conditions
- Graft FailureSickle Cell DiseaseHemoglobinopathies
- Interventions
- Radiation: Total Body IrradiationBiological: Cell Infusion
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 62
- Registration Number
- NCT06872333
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Conditions
- Acquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell AplasiaSevere Aplastic AnemiaParoxysmal Nocturnal Hemoglobinuria
- Interventions
- Radiation: Total Body IrradiationBiological: Cell InfusionDrug: Post-Transplant G-CSF
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 60
- Registration Number
- NCT06412497
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
1 Vs 7 RATG Infusions in Renal Transplantation
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Mario Negri Institute for Pharmacological Research
- Target Recruit Count
- 75
- Registration Number
- NCT06374095
- Locations
- 🇮🇹
ASST HPG23 - Unità di Nefrologia, Bergamo, BG, Italy
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
- Conditions
- Kidney Transplantation
- Interventions
- Drug: Corticosteroids (CS)
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 33
- Registration Number
- NCT06365437
- Locations
- 🇸🇪
Skåne University Hospital, Malmö, Sweden
🇸🇪Sahlgrenska University Hospital, Göteborg, Sweden
🇦🇹Innsbruck Medical University, Innsbruck, Austria
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
- Conditions
- GVHD,AcuteAcute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 29
- Registration Number
- NCT06315309
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
PTCy and ATG for MSD and MUD Transplants
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromesHodgkin LymphomaNon-hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Instituto Nacional de Cancer, Brazil
- Target Recruit Count
- 50
- Registration Number
- NCT06299462
- Locations
- 🇧🇷
Instituto Nacional de Cancer, Rio de Janeiro, Brazil
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
- Conditions
- Myelodysplastic SyndromesAcute LeukemiaSevere Aplastic Anemia
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06279494
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
- Conditions
- Myelodysplastic SyndromeAcute LeukemiaMyeloproliferative Disorders
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 56
- Registration Number
- NCT06265584
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
ATG Plus Low-dose PT-Cy for GVHD Prevention
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 196
- Registration Number
- NCT06108739
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Pediatric Induction Therapy in Kidney Transplantation
- Conditions
- Kidney Transplant RejectionPediatric Kidney Disease
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Gang Chen
- Target Recruit Count
- 958
- Registration Number
- NCT06087003
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University., Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.